Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.
Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.
N K
NK
Ayisi
D000998:Antiviral Agents / Q000494:pharmacology*; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D016049:Didanosine / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D005869:Ghana; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000472:pathogenicity*; D015498:HIV-2 / Q000145:classification / Q000187:drug effects* / Q000472:pathogenicity*; D006801:Humans; D008826:Microbial Sensitivity Tests; D014776:Virus Cultivation; D016047:Zalcitabine / Q000494:pharmacology*
D000998:Antiviral Agents; D016047:Zalcitabine; D016049:Didanosine